The 94 participants were adults with central obesity (excess fat around the waist and abdomen), and they took 10 mg of lutein or a placebo daily for 32 weeks.

Compared with placebo, supplemental lutein reduced diastolic blood pressure (−3.6 mmHg), total cholesterol (−0.5 mmol/L, −19.3 mg/dL), LDL cholesterol (−0.3 mmol/L, −11.6 mg/dL), apolipoprotein B (−0.1 g/L, −10 mg/dL), and malondialdehyde (−0.1 nmol/mL; a marker of oxidative stress).

Lutein also reduced the advanced glycation end products carboxyethyl lysin (−8.76 ng/mL), carboxymethyl lysine (−72.3 ng/mL), and methylglyoxal hydroimidazolone (−233.9 ng/mL).

The lutein manufacturer both supplied the supplement and partially funded this research.

Can supplemental lutein affect cardiometabolic health in people with central obesity? Original paper